Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04456413 · ClinicalTrials.gov registry record · Phase 2
Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection
A Phase 2 study, sponsored by Hackensack Meridian Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT04456413 is a Phase 2 study that was terminated before completion, run by Hackensack Meridian Health. The registered enrollment target is 21 participants.
The verdict
NCT04456413, a Phase 2 study, was terminated before completion, sponsored by Hackensack Meridian Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
* This is a phase II randomized study of convalescent plasma for the treatment of non-immune individuals with COVID-19 infection at high risk of complications. * Subjects will be considered as having completed the study after 2 months (+/- 5) days, unless consent withdrawal or death occurs first. * Subjects will be randomized to receiving convalescent plasma or best supportive care. * Patients randomized to best supportive care may receive plasma should they require hospitalization for progression of COVID-19 disease. * The final analysis will be conducted once the last subject completes the 2-month visit or withdraws from the study.
Interventions
- OTHER Best Supportive Care
- BIOLOGICAL Convalescent Plasma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2020-11-06 |
| Est. Completion | 2021-05-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04456413
The ClinicalTrials.gov registry entry for NCT04456413 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hackensack Meridian Health, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Best Supportive Care is the first listed.
NCT04456413 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04456413 about?
NCT04456413 is a clinical study titled "Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection". * This is a phase II randomized study of convalescent plasma for the treatment of non-immune individuals with COVID-19 infection at high risk of complications. * Subjects will be considered as having completed the study after 2 months (+/- 5) days, unless consent withdrawal or death occurs first. * ...
What is the current status of trial NCT04456413?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2020-11-06. Estimated completion is 2021-05-04.
What interventions are being tested in trial NCT04456413?
The interventions under investigation include: Best Supportive Care (OTHER), Convalescent Plasma (BIOLOGICAL).
Who is sponsoring clinical trial NCT04456413?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.